# TREAT-NMD
> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/TREAT-NMD
> Markdown URL: https://mediated.wiki/source/TREAT-NMD.md
> Source: https://en.wikipedia.org/wiki/TREAT-NMD
> Source revision: 1271526274
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)
{{short description|Global academic network}}
{{Use dmy dates|date=August 2019}}
{{Multiple issues|
{{notability|Companies|date=June 2018}}
{{third-party|date=June 2018}}
}}
{{Research-Project
| name = TREAT-NMD
| title = Translational Research in Europe - Assessment and Treatment of Neuromuscular diseases
| keywords = [Neuromuscular diseases](/source/Neuromuscular_diseases), [clinical research](/source/clinical_research)
| fundingAgency = [European Commission](/source/European_Commission)
| frameworkProgramme = [Sixth Framework Programme](/source/Sixth_Framework_Programme)|image =
| projectType = [Network of Excellence](/source/Network_of_Excellence)
| researchObjective = Improving trial-readiness worldwide, advancing patient diagnosis and care and accelerating pre-clinical research
| projectReference = FP6-036825
| coordinator = Institute of Genetic Medicine, [Newcastle University](/source/Newcastle_University)
| participants = Universities, pharmaceutical companies, patient organisations
| website = {{url|www.treat-nmd.org}}
}}
'''TREAT-NMD''' (Translational Research in Europe, Assessment and Treatment for NeuroMuscular Disorders) is a global academic network that focuses on advancing research in [neuromuscular disorders](/source/Neuromuscular_disease).[{{Cite journal |last1=Leary |first1=Rebecca |last2=Oyewole |first2=Anne |last3=Bushby |first3=Katharine |last4=Aartsma-Rus |first4=Annemieke |date=2017-07-06 |title=Translational Research in Europe for the Assessment and Treatment for Neuromuscular Disorders (TREAT-NMD) | journal=Neuropediatrics |volume=48 |issue=4 |pages=211–220 | pmid = 28683502 |doi=10.1055/s-0037-1604110 |s2cid=19283049 }}] It was established in 2007 with its coordination centre at the [Newcastle University](/source/Newcastle_University).[{{cite journal | first1 = Katharine | last1 = Bushby | first2 = Stephen | last2 = Lynn | first3 = Volker | last3 = Straub | title = Collaborating to bring new therapies to the patient--the TREAT-NMD model | journal = Acta Myologica | volume = 28 | issue = 1 | pages = 12–5 | date = July 2009 | pmid = 19772190 | pmc = 2859629 }}] As of 2018, the network comprises over a hundred research centres and patient organisations from 54 countries[{{cite web |url=http://www.treat-nmd.eu/about/membership/organizations/ |title=TREAT-NMD Alliance Members – Organizations | work = TREAT Neuromuscular Network |access-date=2018-06-13}}] as well as independent academics and patient representatives.[{{Cite web |url=http://www.treat-nmd.eu/about/membership/individuals/ |title=TREAT-NMD Alliance Members – Individuals | work = TREAT Neuromuscular Network |access-date=2018-06-13}}] The network's aim is to provide infrastructure to accelerating research through supporting collaboration between its members.[{{Cite web |url=http://www.treat-nmd.eu/about/network/about-network/ |title=TREAT-NMD : About the TREAT-NMD network | work = TREAT Neuromuscular Network }}] Its main goals include improving trial-readiness worldwide, advancing patient diagnosis and care and accelerating pre-clinical research.[{{cite journal | first1 = Raffaella | last1 = Willmann | first2 = Markus A. | last2 = Rüegg | first3 = Rebecca J. | last3 = Fairclough | first4 = Kay E | last4 = Davies | first5 = Stefanie | last5 = Possekel | first6 = Thomas | last6 = Meier |title=T.P.3.03 TREAT-NMD-Activity 7: Accelerate preclinical phase of new therapeutic treatment development |journal=Neuromuscular Disorders |date=October 2008 |volume=18 |issue=9–10 |pages=794 |doi=10.1016/j.nmd.2008.06.242 | s2cid = 54330245 |type=Conference abstract}}][{{cite journal | first1 = Eugenio Maria | last1 = Mercuri | first2 = Anna G | last2 = Mayhew | first3 = Francesco | last3 = Muntoni | first4 = Volker | last4 = Straub | first5 = Gert-Jan | last5 = Van Ommen | first6 = Thomas | last6 = Voit | first7 = Enrico | last7 = Bertini | first8 = Katherine | last8 = Bushby | title = Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREAT-NMD/ENMC workshop on outcome measures, 12th--13th May 2007, Naarden, The Netherlands; TREAT-NMD workshop on outcome measures in experimental trials for DMD, 30th June--1st July 2007, Naarden, The Netherlands; conjoint Institute of Myology TREAT-NMD meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France | journal = Neuromuscular Disorders | volume = 18 | issue = 11 | pages = 894–903 | date = November 2008 | pmid = 18818076 | doi = 10.1016/j.nmd.2008.07.003 |type=Workshop report | doi-access = free }}]
Through [patient registries](/source/patient_registries), TREAT-NMD provides [genotype](/source/genotype)–[phenotype](/source/phenotype) correlation between [genetic mutation](/source/genetic_mutation)s and neuromuscular disease burden.[{{cite book | vauthors = Thompson R, Robertson A, Lochmüller H | title = Rare Diseases Epidemiology: Update and Overview | chapter = Natural History, Trial Readiness and Gene Discovery: Advances in Patient Registries for Neuromuscular Disease | series = Advances in Experimental Medicine and Biology | volume = 1031 | pages = 97–124 | date = 2017 | pmid = 29214567 | doi = 10.1007/978-3-319-67144-4_5 | isbn = 978-3-319-67142-0 }}]
==References==
{{reflist|30em}}
==Further reading==
{{refbegin}}
*{{Cite journal |last1=Heslop |first1=Emma |last2=Csimma |first2=Cristina |last3=Straub |first3=Volker |last4=McCall |first4=John |last5=Nagaraju |first5=Kanneboyina |last6=Wagner |first6=Kathryn R. |last7=Caizergues |first7=Didier |last8=Korinthenberg |first8=Rudolf |last9=Flanigan |first9=Kevin M. |date=2015-04-23 |title=The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development |journal=Orphanet Journal of Rare Diseases |volume=10 |issue=1 |pages=49 |doi=10.1186/s13023-015-0258-1 |pmc= 4417237 |pmid=25902795 |doi-access=free }}
*{{Cite journal |last1=Bladen |first1=Catherine L. |last2=Rafferty |first2=Karen |last3=Straub |first3=Volker |last4=Monges |first4=Soledad |last5=Moresco |first5=Angélica |last6=Dawkins |first6=Hugh |last7=Roy |first7=Anna |last8=Chamova |first8=Teodora |last9=Guergueltcheva |first9=Velina |date=2013-08-26 |title=The TREAT-NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia |journal=Human Mutation |volume=34 |issue=11 |pages=1449–1457 | pmid = 23913485 |doi=10.1002/humu.22390 |s2cid=38772058 |doi-access=free }}
*{{cite journal |last1=Aartsma-Rus |first1=Annemieke |last2=Mercuri |first2=Eugenio |last3=Vroom |first3=Elizabeth |last4=Balabanov |first4=Pavel | title = Meeting report of the "Regulatory Exchange Matters" session at the 5th International TREAT-NMD Conference:: Lessons in communication: How an early dialogue between patients, regulators and academics can further therapy development for neuromuscular disorders Freiburg, Germany, 27-29 November 2017 | journal = Neuromuscular Disorders | volume = 28| issue = 7| pages = 619–623| date = April 2018 | pmid = 29778308 | doi = 10.1016/j.nmd.2018.04.009 |doi-access=free }}
{{refend}}
Category:Medical research organizations
---
Adapted from the Wikipedia article [TREAT-NMD](https://en.wikipedia.org/wiki/TREAT-NMD) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/TREAT-NMD?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.